An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

To be considered for this study, you would first need to have a clear diagnosis of Guillain-Barré Syndrome (GBS) confirmed by doctors, following specific national guidelines. It's important that your GBS-related muscle weakness started no more than 10 days before the study treatment begins. Also, your current level of weakness needs to be a certain severity, meaning you have significant difficulty moving around or are unable to walk without help.

There are also some reasons why you might not be able to join. For example, if you have already received common GBS treatments like plasma exchange or IV immunoglobulin (IVIg) within the last 90 days, or if you are planning to have them, you wouldn't be eligible. The study is specifically for the most common form of GBS that affects your arms and legs, so if your GBS only affects other parts of your body, you wouldn't be able to take part.

Other health conditions or medications might also mean you can't join, but the study team would discuss all of this with you in detail to see if the study is right for your situation.

If you decide to take part in this study, you would receive the study medicine, Tanruprubart, through an infusion (like a drip into your arm). The study team would closely monitor you, especially during and after the infusions, to check for any side effects and see how you are responding. You would have several visits to the clinic for assessments, which might include physical examinations, blood tests, and tests to check your muscle strength and movement. The study involves regular follow-up visits over a period of time to track your progress. The total duration of your participation would be explained fully by the study team, but it typically involves several months of observation and visits. You'll be given all the details about the schedule and what's involved if you are eligible and interested.